| Literature DB >> 24916650 |
Jorie Versmissen1, Daniëlla M Oosterveer1, Mojgan Yazdanpanah1, Abbas Dehghan2, Hilma Hólm3, Jeanette Erdman4, Yurii S Aulchenko5, Gudmar Thorleifsson3, Heribert Schunkert4, Roeland Huijgen6, Ranitha Vongpromek1, André G Uitterlinden7, Joep C Defesche6, Cornelia M van Duijn2, Monique Mulder1, Tony Dadd8, Hróbjartur D Karlsson9, Jose Ordovas10, Iris Kindt11, Amelia Jarman8, Albert Hofman2, Leonie van Vark-van der Zee1, Adriana C Blommesteijn-Touw1, Jaap Kwekkeboom12, Anho H Liem13, Frans J van der Ouderaa14, Sebastiano Calandra15, Stefano Bertolini16, Maurizio Averna17, Gisle Langslet18, Leiv Ose18, Emilio Ros19, Fátima Almagro20, Peter W de Leeuw21, Fernando Civeira22, Luis Masana23, Xavier Pintó24, Maarten L Simoons25, Arend F L Schinkel26, Martin R Green8, Aeilko H Zwinderman27, Keith J Johnson28, Arne Schaefer29, Andrew Neil30, Jacqueline C M Witteman2, Steve E Humphries31, John J P Kastelein6, Eric J G Sijbrands1.
Abstract
Mutations in the low-density lipoprotein receptor (LDLR) gene cause familial hypercholesterolemia (FH), a disorder characterized by coronary heart disease (CHD) at young age. We aimed to apply an extreme sampling method to enhance the statistical power to identify novel genetic risk variants for CHD in individuals with FH. We selected cases and controls with an extreme contrast in CHD risk from 17,000 FH patients from the Netherlands, whose functional LDLR mutation was unequivocally established. The genome-wide association (GWA) study was performed on 249 very young FH cases with CHD and 217 old FH controls without CHD (above 65 years for males and 70 years of age for females) using the Illumina HumanHap550K chip. In the next stage, two independent samples (one from the Netherlands and one from Italy, Norway, Spain, and the United Kingdom) of FH patients were used as replication samples. In the initial GWA analysis, we identified 29 independent single nucleotide polymorphisms (SNPs) with suggestive associations with premature CHD (P<1 × 10(-4)). We examined the association of these SNPs with CHD risk in the replication samples. After Bonferroni correction, none of the SNPs either replicated or reached genome-wide significance after combining the discovery and replication samples. Therefore, we conclude that the genetics of CHD risk in FH is complex and even applying an 'extreme genetics' approach we did not identify new genetic risk variants. Most likely, this method is not as effective in leveraging effect size as anticipated, and may, therefore, not lead to significant gains in statistical power.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24916650 PMCID: PMC4326701 DOI: 10.1038/ejhg.2014.101
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246